Clinical Evaluation of a Tubal Selective Delivery System

NCT05775913 | Not Yet Recruiting

• 1 other identifier: OHSU IRB 24448
• Study Type: interventional
• Target: 12
• Locations: 0 countries
• Sites: N/A

Brief Summary

A single center study to evaluate the performance and optimize the design of a novel intrauterine catheter system intended as a nonsignificant risk medical device to aid in evaluating tubal patency as part of the initial diagnostic workup for infertility.

Conditions

Infertility of Tubal Origin

Outcome Measures

Primary Outcomes (6)

• Clinical performance of catheter during insertion of device

  Clinician impression of catheter performance during insertion of device. Performance is categorized as one of three levels: excellent, acceptable, or fail. The number of participants in each category will be reported, with categories defined as: Excellent: Clinician can place the insertion tube transcervically without dilation, and advance the obturator to expand the device without the use of imaging guidance. Acceptable: Cervical dilation required, but easy to advance the obturator to expand the device without the use of imaging guidance Fail: Unable to place the insertion tube

  Immediately post-procedure within 30 minutes

• Expansion of arms and dual catheters

  Expansion of arms and dual catheters in the two uterine cornua. Performance is categorized as one of three levels: excellent, acceptable, or fail. The number of participants in each category will be reported, with categories defined as: Excellent: Arms extend into bilateral cornua following transcervical insertion after initial expansion. Ultrasound confirms extension but is not needed Acceptable: Ultrasound is required to position arms, but expansion is successful after one or two attempts. Fail: Clinician is unable to position arms into cornua.

  During procedure immediately following attempt to position device

• Inflation of dual balloons

  Inflation of the dual balloons. Performance is categorized as one of three levels: excellent, acceptable, or fail. The number of participants in each category will be reported, with categories defined as: Excellent: Inflation of the dual balloons on first attempt by the clinician with no leakage or bad connections. This is confirmed by ultrasound. Acceptable: Inflation requires more than one attempt but is ultimately successful. Fail: Clinician is unable to inflate balloons due to high pressure or subject pain.

  During procedure immediate following attempt to inflate balloons

• Delivery of saline

  Delivery of saline. Performance is categorized as one of three levels: excellent, acceptable, or fail. The number of participants in each category will be reported, with categories defined as: Excellent: Successful administration of saline at low pressure (confirmed by ultrasound) with no leakage or bad connections. Acceptable: Some leakage of saline, but clinician is able to observe flow in tubes. Fail: Clinician unable to administer saline due to high pressure/pain, leakage or bad connections.

  During procedure immediate following attempt to administer saline

• Delivery of ExEm foam

  Delivery of ExEm foam. Performance is categorized as one of three levels: excellent, acceptable, or fail. The number of participants in each category will be reported, with categories defined as: Excellent: Delivery of foam at low pressure with confirmation of tubal patency via ultrasound and with no leakage or bad connections. Acceptable: Some leakage of ExEm in uterine cavity, but clinician is able to observe flow in tubes. Fail: Clinician unable to administer ExEm due to high pressure/pain, leakage or bad connections.

  During procedure immediate following attempt to administer ExEm foam

• Clinician impression of device removal

  Clinician impression of device removal. Performance is categorized as one of three levels: excellent, acceptable, or fail. The number of participants in each category will be reported, with categories defined as: Excellent: Clinician can deflate balloons, collapse frame, and withdraw insertion tube without difficulty at the end of procedure without the use of imaging guidance.

  During procedure immediate following attempt remove device

Secondary Outcomes (2)

• Tolerability and ease of use - Provider experience evaluation

  Immediately Post-procedure (within 30 minutes)

• Tolerability and ease of use - Patient experience evaluation

  Pre-procedure, during procedure, immediately post-procedure, 15 minutes post-procedure

Study Arms (1)

Tubal Selective Delivery System

EXPERIMENTAL

The same intervention will be used for all study subjects.

Device: Tubal Selective Delivery System (TSDS)

Interventions

Tubal Selective Delivery System (TSDS) DEVICE

A novel tubal selective delivery catheter system for selective delivery of administered agents to the fallopian tubes without entry of any portion of the catheter into the tubes.

Tubal Selective Delivery System

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Literate in English
• Able to understand and sign an IRB-approved informed consent form
• Willing to complete a pre-procedure questionnaire
• Regular menstrual cycles (24- 38 days)
• Good general health
• Able and willing to comply with all study tests, procedures, and assessment tools
• Uterine sound size between 6 - 10 cm
• Agree to use a non-hormonal method of contraception or avoid vaginal intercourse during the catheter evaluation cycle
• In compliance with cervical cancer screening guidelines per the American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines without evidence of disease.
• Alternatively, the subject must have had a colposcopy performed within the appropriate screen time frame, and prior to the study catheter insertion that showed no evidence of dysplasia requiring treatment or further diagnostic procedures or follow-up for at least 6 months

You may not qualify if:

• Currently pregnant as confirmed by positive high-sensitivity urine pregnancy test
• Currently using hormonal contraception. Must have at least one natural cycle (two menses) prior to participation if recently discontinued hormonal contraception.
• Currently using an intrauterine device (IUD). Must discontinue at least 30 days prior to Visit 2
• History or physical findings recognized as clinically significant by the investigator, such as symptoms of untreated or recent pelvic infection
• History of involuntary female infertility
• History of gynecologic surgery involving the uterus, fallopian tubes, or ovaries (except single cesarean section)
• History of prior permanent contraception procedure (any technique, abdominal laparoscopic, or hysteroscopic)
• Pelvic exam findings considered clinically-significant by the investigator such as uterine fibroids, pelvic tenderness, or prolapse
• Inability to tolerate placement of a tenaculum and/or uterine sound during screening exam
• Any congenital or acquired uterine anomaly that may complicate study drug placement, such as:
• Submucosal uterine leiomyoma
• Asherman's syndromes
• Pedunculated polyps
• Bicornuate uterus
• Didelphys or uterine septa

Sponsors & Collaborators

• Oregon Health and Science University: lead

Study Officials

• Jeffrey Jensen, MD

  Oregon Health and Science University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Women's Health Research Unit Department of Ob/Gyn

CONTACT

503-494-3666; whru@ohsu.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SCREENING
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: September 22, 2022
• First Posted: March 20, 2023
• Study Start (Estimated): December 1, 2026
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): March 1, 2028
• Last Updated: July 31, 2025

Record last verified: 2025-07